The Use of Muscle Relaxants After Chemotherapy and Radiotherapy

References

• Zeien J, Qiu W, Triay M, et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacoth. 2022;146:112503. doi:10.1016/j.biopha.2021.112503
   PubMed Web of Science ®Google Scholar
• Sane S, Sinaei B, Golabi P, et al. The neurologic complications associated with anesthesia in pediatrics treated with radiotherapy under anesthesia. Iranian J Paediatr. 2022;32:1.
   Web of Science ®Google Scholar
• Chung F. Cancer, chemotherapy and anaesthesia. Canad Anaesthet Society J. 1982;29:364–371.
   PubMedGoogle Scholar
• O’Reilly M, Mellotte G, Ryan B, et al. Gastrointestinal side effects of cancer treatments. Therap Adv Chronic Disease. 2020;11:2040622320970354.
   Web of Science ®Google Scholar
• Rosner MH. Chronic Kidney Disease and Cancer. In: Management of Chronic Kidney Disease: A Clinician’s Guide. Cham: Springer International Publishing; 2023:485–498.
   Google Scholar
• Plaud B, Baillard C, Bourgain J-L, et al. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020;39(1):125–142. doi:10.1016/j.accpm.2020.01.005
   PubMed Web of Science ®Google Scholar
• Fuchs-Buder T, Romero CS, Lewald H, et al. Peri-operative management of neuromuscular blockade: a guideline from the European society of anaesthesiology and intensive care. Europ J Anaesthesiol. 2023;40(2):82–94. doi:10.1097/EJA.0000000000001769
   PubMed Web of Science ®Google Scholar
• Knezevic CE, Clarke W. Cancer chemotherapy: the case for therapeutic drug monitoring. Ther Drug Monit. 2020;42(1):6–19. doi:10.1097/FTD.0000000000000701
   PubMed Web of Science ®Google Scholar
• Hager HH, Burns B. Succinylcholine Chloride. In: StatPearls. Treasure Island (FL);: StatPearls Publishing; 2022. PMID: 29763160.
   Google Scholar
• Gulenay M, Mathai JK. Depolarizing Neuromuscular Blocking Drugs. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 30422589.
   Google Scholar
• Al-Khafaji AH, Dewhirst WE, Cornell CJ, et al. Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy. Crit Care Med. 2001;29(6):1274–1276. doi:10.1097/00003246-200106000-00040
   PubMed Web of Science ®Google Scholar
• Bryson EO, Aloysi AS, Perez AM, et al. Prolonged succinylcholine action during electroconvulsive therapy (ECT) after cytarabine, vincristine, and rituximab chemotherapy. The J ECT. 2011;27(1):e42–e43. doi:10.1097/YCT.0b013e3181ff2e47
   PubMed Web of Science ®Google Scholar
• BOOIJ LHDJ, DROBNIK L. Variability in the effect of muscle relaxants. Factors involved in the pharmacodynamic profile of neuromuscular blocking agents. Part II Zmienność działania środków zwiotczających. Anestezjol I Ratow. 2009;3:154–184.
   Google Scholar
• Chougule A, Hussain S, Agarwal DP. Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther. 2008;4(1):21–25. doi:10.4103/0973-1482.39601
   PubMed Web of Science ®Google Scholar
• Prabhu K, Naik D. Significance of serum butyrylcholinesterase levels in oral cancer. Australas Med J. 2011;4(7):374. doi:10.4066/AMJ.2011.569
   PubMedGoogle Scholar
• Bradamante V, Šmigovec E, Buković D, et al. Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy. Coll Antropol. 2000;24(2):373–380.
   PubMedGoogle Scholar
• Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplant. 1999;24(12):1367–1368. doi:10.1038/sj.bmt.1702097
   PubMed Web of Science ®Google Scholar
• Das GN, Sharma P, Maani CV. Pancuronium. In: In StatPearls. StatPearls Publishing; 2022.
   Google Scholar
• Chen R, Sun Y, Li Y, et al. Neuromuscular blocking agents and cancer: a narrative review. J Clin Pharm Therapeutics. 2023;2023:1–7. doi:10.1155/2023/5607134
   Web of Science ®Google Scholar
• de Gouw NE, Crul JF, Vandermeersch E, et al. Interaction of antibiotics on pipecuronium-induced neuromuscular blockade. J Clin Anesth. 1993;5(3):212–215. doi:10.1016/0952-8180(93)90017-9
   PubMed Web of Science ®Google Scholar
• Groenewold MD, Olthof CG, Bosch DJ. Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy. BJA Educ. 2022;22(1):12. doi:10.1016/j.bjae.2021.08.002
   PubMed Web of Science ®Google Scholar
• Tassonyi E, Szabo G, Vereczkey L. Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. Arzneim Forschung. 1981;31(10):1754–1756.
   PubMed Web of Science ®Google Scholar
• Pittet JF, Tassony I, Schopfer C, et al. Dose requirements and plasma concentrations of pipecuronium during bilateral renal exclusion and orthotopic liver transplantation in pigs. British J Anaesth. 1990;65(6):779–785. doi:10.1093/bja/65.6.779
   PubMed Web of Science ®Google Scholar
• Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol. 2010;9(2):133–143. doi:10.1016/S1665-2681(19)31651-5
   PubMed Web of Science ®Google Scholar
• Jedeikin R, Dolgunski E, Kaplan R, et al. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. Anaesthesia. 1987;42(8):858–860. doi:10.1111/j.1365-2044.1987.tb04111.x
   PubMed Web of Science ®Google Scholar
• Adachi T, Shinomura T, Nomura R. Duration of vecuronium‐induced neuromuscular blockade is shortened during hyperthermic intraoperative intraperitoneal chemotherapy. Br J Anaesth. 2003;91(1):160–161. doi:10.1093/bja/aeg580
   PubMed Web of Science ®Google Scholar
• Jain A, Wermuth HR. Rocuronium; 2019.
   Google Scholar
• Matsui M, Makimoto A, Chin M, et al. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized Phase 2 trial. Contemp Clin Trials Commun. 2023;2023:1.
   Google Scholar
• Czarnetzki C, Albrecht E, Masouyé P, et al. Rapid sequence induction with a standard intubation dose of rocuronium after magnesium pretreatment compared with succinylcholine: a randomized clinical trial. Obstet Anesth Dig. 2022;42(2):98. doi:10.1097/01.aoa.0000827952.87779.7b
   Google Scholar
• Kim JH, Min KT, Ahn EK, et al. The infusion rate of mivacurium or atracurium for cesarean section compared with gynecological procedures. Yonsei Medi J. 1999;40(4):371–376. doi:10.3349/ymj.1999.40.4.371
   PubMed Web of Science ®Google Scholar
• Jonker G, Hoogenboom LJ, van Ramshorst B, et al. Atracurium during induced hyperthermia. J Clin Anesth. 2009;23:442–444. doi:10.1007/s00540-009-0773-0
   Google Scholar
• Flynn PJ, Frank M, Hughes R. Use of atracurium in caesarean section. Brit J Anaesth. 1984;56(6):599–605. doi:10.1093/bja/56.6.599
   PubMed Web of Science ®Google Scholar
• Spina R, Voss D, Asnaghi L, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016;7(1):459. doi:10.18632/oncotarget.6314
   PubMedGoogle Scholar
• Gupta S, Dubey M. Neuromuscular blockade characteristics of cisatracurium in patients receiving chemotherapy: a preliminary study in breast cancer patients. J Anaesthesiol Clin Pharmacol. 2023;39:577–582. doi:10.4103/joacp.joacp_104_22
   PubMed Web of Science ®Google Scholar
• Zanjani AP, Maghsoudloo M, Makarem J, et al. Chemotherapy alters cisatracurium induced neuromuscular blockade characteristics: a prospective cohort study. J Clin Anesth. 2017;36:84–87. doi:10.1016/j.jclinane.2016.10.025
   PubMed Web of Science ®Google Scholar
• Chung DY, Hardman J. Prolonged paralysis following mivacurium administration. Anaesth Inten Care. 2002;30(3):360–363. doi:10.1177/0310057X0203000316
   PubMed Web of Science ®Google Scholar
• Lian Y, Jiang H, Yuan X, et al. Effects of neoadjuvant chemotherapy on the pharmacodynamics of rocuronium bromide in patients undergoing gastric cancer surgery. Chin J Clin Pharmacology and Ther. 2019;2019:1161.
   Google Scholar
• Liu C, Liu S. Effect of SIRS, sepsis and chemotherapy on rocuronium muscle relaxation: a case series and literature review; 2022.
   Google Scholar